...
首页> 外文期刊>eLife journal >Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
【24h】

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface

机译:抑制剂诱导的HER2-HER3异二聚化通过新型二聚体界面促进增殖

获取原文
   

获取外文期刊封面封底 >>

       

摘要

While targeted therapy against HER2 is an effective first-line treatment in HER2 + breast cancer, acquired resistance remains a clinical challenge. The pseudokinase HER3, heterodimerisation partner of HER2, is widely implicated in the resistance to HER2-mediated therapy. Here, we show that lapatinib, an ATP-competitive inhibitor of HER2, is able to induce proliferation cooperatively with the HER3 ligand neuregulin. This counterintuitive synergy between inhibitor and growth factor depends on their ability to promote atypical HER2-HER3 heterodimerisation. By stabilising a particular HER2 conformer, lapatinib drives HER2-HER3 kinase domain heterocomplex formation. This dimer exists in a head-to-head orientation distinct from the canonical asymmetric active dimer. The associated clustering observed for these dimers predisposes to neuregulin responses, affording a proliferative outcome. Our findings provide mechanistic insights into the liabilities involved in targeting kinases with ATP-competitive inhibitors and highlight the complex role of protein conformation in acquired resistance.
机译:尽管针对HER2的靶向治疗是HER2 +乳腺癌的有效一线治疗,但获得性耐药仍是临床挑战。 HER2的异源二聚体伴侣假激酶HER3与HER2介导的治疗耐药性密切相关。在这里,我们显示拉帕替尼,一种具有ATP竞争性的HER2抑制剂,能够与HER3配体神经调节蛋白协同诱导增殖。抑制剂和生长因子之间这种反直觉的协同作用取决于它们促进非典型HER2-HER3异二聚化的能力。通过稳定特定的HER2构象异构体,拉帕替尼可驱动HER2-HER3激酶结构域异源复合物的形成。该二聚体以不同于标准非对称活性二聚体的头对头方向存在。对于这些二聚体观察到的相关聚类倾向于神经调节蛋白应答,从而提供了增殖结果。我们的发现为利用ATP竞争性抑制剂靶向激酶所涉及的负债提供了机械学见解,并突出了蛋白构象在获得性耐药中的复杂作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号